Patents by Inventor Richard James D'Andrea

Richard James D'Andrea has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110123502
    Abstract: A method for generating a population of functional regulatory T cells (TREG-cells), which are a subset of the T cell lineage having the ability to actively suppress immune activation and maintain peripheral immune tolerance, is described. The method comprises the steps of first culturing haemopoietic stem cells (HSC) and/or haemopoietic progenitor cells in the presence of a Notch ligand that supports T cell differentiation, and then isolating T cells having a TREG-cell surface marker phenotype. A suitable source of HSC is cord blood (CB) and a suitable culture medium is OP9 cells engineered to express the Notch Ligand Delta-Like 1 (DL1) (OP9-DL1 cell line). Examples of TREG-cell surface marker phenotypes are CD4+CD25+, CD45RO+, CD45RA+, CD127LOW?, LAG-3 and/or CD39+.
    Type: Application
    Filed: August 30, 2007
    Publication date: May 26, 2011
    Inventors: Simon C. Barry, Richard James D'Andrea, Jonathon F. Hutton
  • Patent number: 7112427
    Abstract: The present invention relates generally to novel protein molecules and to derivatives, analogues, chemical equivalents and mimetics thereof capable of modulating cellular activity and, in particular, modulating cellular activity via the modulation of signal transduction. More particularly, the present invention relates to human sphingosine kinase and to derivatives, analogues, chemical equivalents and mimetics thereof. The present invention also contemplates genetic sequences encoding said protein molecules and derivatives, analogues, chemical equivalents and mimetics thereof. The molecules of the present invention are useful in a range of therapeutic, prophylactic and diagnostic applications.
    Type: Grant
    Filed: August 18, 2003
    Date of Patent: September 26, 2006
    Assignee: Johnson & Johnson Pharmaceutical Research and Development LLC
    Inventors: Stuart Maxwell Pitson, Brian Wolff Wattenberg, Pu Xia, Richard James D'Andrea, Jennifer Ruth Gamble, Matthew Alexander Vadas
  • Publication number: 20040132053
    Abstract: The present invention relates generally to novel protein molecules and to derivatives, analogues, chemical equivalents and mimetics thereof capable of modulating cellular activity and, in particular, modulating cellular activity via the modulation of signal transduction. More particularly, the present invention relates to human sphingosine kinase and to derivatives, analogues, chemical equivalents and mimetics thereof. The present invention also contemplates genetic sequences encoding said protein molecules and derivatives, analogues, chemical equivalents and mimetics thereof. The molecules of the present invention are useful in a range of therapeutic, prophylactic and diagnostic applications.
    Type: Application
    Filed: August 18, 2003
    Publication date: July 8, 2004
    Applicant: Johnson & Johnson Pharmaceutical R and D LLC
    Inventors: Stuart Maxwell Pitson, Brian Wolff Wattenberg, Pu Xia, Richard James D'Andrea, Jennifer Ruth Gamble, Matthew Alexander Vadas
  • Patent number: 6730480
    Abstract: The present invention relates generally to novel protein molecules and to derivatives, analogues, chemical equivalents and mimetics thereof capable of modulating cellular activity and, in particular, modulating cellular activity via the modulation of signal transduction. More particularly, the present invention relates to human sphingosine kinase and to derivatives, analogues, chemical equivalents and mimetics thereof. The present invention also contemplates genetic sequences encoding said protein molecules and derivatives, analogues, chemical equivalents and mimetics thereof. The molecules of the present invention are useful in a range of therapeutic, prophylactic and diagnostic application.
    Type: Grant
    Filed: January 24, 2002
    Date of Patent: May 4, 2004
    Assignee: Johnson & Johnson Pharmaceutical Research and Development LLC
    Inventors: Stuart Maxwell Pitson, Brian Wolff Wattenberg, Pu Xia, Richard James D'Andrea, Jennifer Ruth Gamble, Matthew Alexander Vadas